<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03686306</url>
  </required_header>
  <id_info>
    <org_study_id>VIRTUOSE</org_study_id>
    <secondary_id>2020-000231-42</secondary_id>
    <secondary_id>20 07 41</secondary_id>
    <secondary_id>MEDAECNAT-2020-07- 00008</secondary_id>
    <nct_id>NCT03686306</nct_id>
  </id_info>
  <brief_title>VIRTUOSE : Efficiency of Sildenafil on the Absolute Claudication Distance of Peripheral Arterial Disease Patients With Intermittent Claudication.</brief_title>
  <acronym>VIRTUOSE</acronym>
  <official_title>VIRTUOSE : Efficiency of Sildenafil on the Absolute Claudication Distance of Peripheral Arterial Disease Patients With Intermittent Claudication. A Phase III, National, Multicentre, Prospective, Randomised, Double-blind, Placebo-Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Peripheral Arterial Disease (PAD) is a highly debilitating disease that affects 202 million&#xD;
      people around the world and about 7 million people in France. Morbi-mortality from&#xD;
      cardiovascular events is increased in this population. Intermittent claudication is defined&#xD;
      as a discomfort and/or pain in the legs during walking. It is the most common clinical&#xD;
      feature of PAD.&#xD;
&#xD;
      In claudication, primary therapeutic approach is medical treatment and advice to walk.&#xD;
      Revascularization is only proposed when medical treatment and advice to walk for at least 3&#xD;
      to 6 months have failed to improve symptoms and walking ability.&#xD;
&#xD;
      Optimal medical treatment includes Antiplatelet, Lipid Lowering Drugs, AT2 antagonists / ACE&#xD;
      Inhibitors and advice to walk.&#xD;
&#xD;
      To date, no other drug has provided consistent evidence for functional improvement in&#xD;
      claudication, except for Cilostazol, a type-3 phospho-diesterase inhibitor (PDEi). This&#xD;
      compound has been scarcely used in France due to cost and frequent side effect (Headache,&#xD;
      Flush, Diarrhea, etc.) and was withdrawn as a therapy in 2010.&#xD;
&#xD;
      Sildenafil, a type 5 PDEi, is well tolerated, largely used in impotence and has interesting&#xD;
      clinical delay and duration of action in the concept of a potential use in claudication.&#xD;
      Preliminary data from the literature and unpublished case reports, suggest that this drug&#xD;
      could efficiently improve symptoms and walking capacity in patients with stage 2&#xD;
      claudication.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Experimental design A Phase III, National, Multicentre, Prospective, Randomised, Double&#xD;
      Blind, placebo-controlled clinical trial with two parallel groups.&#xD;
&#xD;
      Eligible patients will be randomised in two groups:&#xD;
&#xD;
        -  Experimental group Sildenafil citrate 140 mg/day (single morning oral dose of 140 mg)&#xD;
           for a total duration of 24 weeks.&#xD;
&#xD;
        -  Control group Placebo (single morning oral dose) for a total duration of 24 weeks.&#xD;
&#xD;
      Treatment will be proposed in addition to optimal treatment (Antiplatelet + Lipid Lowering&#xD;
      Drugs + AT2 antagonists / ACE Inhibitors; unless contra-indicated) + advice to walk.&#xD;
&#xD;
      The experimental drug will be delivered for a 4 weeks treatment period. Phone contact will be&#xD;
      carried out at 7 and 14 days focusing on tolerance, compliance and eventual side effects.&#xD;
&#xD;
      First follow up visit at week 4 will focus on tolerance, compliance and side effects. If no&#xD;
      major side effect is found, the study drug will be delivered for an additional 8 weeks.&#xD;
&#xD;
      Phone contact will be carried out at 8 weeks focusing on tolerance, compliance and eventual&#xD;
      side effects.&#xD;
&#xD;
      Patients will be evaluated at week 12 (second follow-up visit) for persistent or&#xD;
      non-persistent indication for revascularization and considered for revascularization if&#xD;
      needed. In parallel, attention will be given to tolerance, compliance and eventual side&#xD;
      effects. If no major side effect is found, the study drug will be delivered for an additional&#xD;
      12 weeks period.&#xD;
&#xD;
      Phone contact will be carried out at weeks 16 and 20 focusing on tolerance, compliance and&#xD;
      eventual side effects.&#xD;
&#xD;
      Third and fourth follow-up visits are scheduled at week 24 (end of treatment) and week 48 (24&#xD;
      weeks after the end of experimental drugs).&#xD;
&#xD;
      Perspectives&#xD;
&#xD;
        -  Improving quality of life of patients suffering a chronic debilitating disease is a&#xD;
           major issue not only in vascular medicine.&#xD;
&#xD;
        -  It is expected that the treatment may help patients change from a vicious circle (Pain &gt;&#xD;
           inactivity &gt; disease progression &gt; pain &gt; increased morbi-mortality) to a virtuous&#xD;
           circle (no Pain &gt; improved ability for activity &gt; collateral vessel development &gt;&#xD;
           slowing of disease progression &gt; decreased morbi-mortality )&#xD;
&#xD;
        -  We expect that half of the patients that fulfil inclusion criteria will be sufficiently&#xD;
           improved not to require surgery anymore even 24 weeks after the end of the drug as a&#xD;
           result of this virtuous circle.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 28, 2021</start_date>
  <completion_date type="Anticipated">May 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 28, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Experimental design A Phase III, National, Multicentre, Prospective, Randomised, Double Blind, placebo-controlled clinical trial with two parallel groups.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>The preparation of the 'blinded' treatments will be undertaken by the PPRIGO hospital pharmacist's consortium (Production Pharmaceutique pour la Recherche Institutionnelle du Grand Ouest) under recommended standardised conditions. PPRIGO will provide numbered and labelled boxes each containing 32 capsules of the study drug (sildenafil or placebo according to the randomisation order). All boxes will be identically labelled, with the study number being the only differentiating feature between different drug packs.&#xD;
The un-blinding will be centralised with eCRF software in agreement with the principal investigator.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute claudication distance</measure>
    <time_frame>Baseline and week 24</time_frame>
    <description>Absolute change of the absolute claudication distance (ACD) from baseline to week 24</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surgical re-vascularisation</measure>
    <time_frame>baseline and weeks 24 and 48</time_frame>
    <description>Rate of patients with surgical re-vascularisation at weeks 24 and 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACD</measure>
    <time_frame>Baseline and week 48</time_frame>
    <description>Absolute change of the ACD from baseline to week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event free survival (EFS)</measure>
    <time_frame>Through the study completion, an average of 1 year</time_frame>
    <description>An &quot;EVENT&quot; is defined as either (1) major adverse cardiovascular events (MACE; including vascular deaths, non-fatal myocardial infarction and non-fatal stroke), (2) leg amputations, (3) Non Cardiovascular death.&#xD;
Event-free survival is defined as the time from inclusion to the first documented event. If no event is observed, event-free survival is defined as the delay of follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>36-Item Short Form Health Survey (SF36)</measure>
    <time_frame>Baseline and weeks 12, 24 and 48</time_frame>
    <description>Quality of life : SF36 questionnaire at baseline and weeks 12, 24 and 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral Artery Questionnaire</measure>
    <time_frame>Baseline and weeks 12, 24 and 48</time_frame>
    <description>Peripheral Artery Questionnaire at baseline and weeks 12, 24 and 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxymetry</measure>
    <time_frame>Baseline and weeks 12, 24 and 48</time_frame>
    <description>Change in exercise oxymetry results between baseline and weeks 12, 24 and 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial function by Laser Speckle</measure>
    <time_frame>Baseline and weeks 12, 24 and 48</time_frame>
    <description>Change in endothelial function at weeks 12, 24 and 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function</measure>
    <time_frame>Baseline and week 24</time_frame>
    <description>Pulmonary function and diffusion capacity of the lungs for carbon monoxide (DLCO) at week 24 from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respect of prescribed dose</measure>
    <time_frame>Through the study completion, an average of 1 year</time_frame>
    <description>Compliance with the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance</measure>
    <time_frame>Through the study completion, an average of 1 year</time_frame>
    <description>Tolerance and side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial stifness</measure>
    <time_frame>Baseline and weeks 12, 24 and 48</time_frame>
    <description>Changes in arterial stiffness (Pulse Wave Velocity) with pOpmetre® between baseline and weeks 12, 24 and 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central Blood Pressure</measure>
    <time_frame>Baseline and weeks 12, 24 and 48</time_frame>
    <description>Changes in Central Blood Pressure with pOpmetre® between baseline and weeks 12, 24 and 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial compliance</measure>
    <time_frame>Baseline and weeks 12, 24 and 48</time_frame>
    <description>Changes in arterial compliance with Finometer® between baseline and weeks 12, 24 and 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular resistance</measure>
    <time_frame>Baseline and weeks 12, 24 and 48</time_frame>
    <description>Changes in vascular resistance with Finometer® between baseline and weeks 12, 24 and 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolomics signature</measure>
    <time_frame>Baseline and week 24</time_frame>
    <description>Change in metabolomics signature between baseline and week 24</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sildenafil citrate 140 mg/day (single morning oral dose of 140 mg) for a total duration of 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (single morning oral dose) for a total duration of 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil</intervention_name>
    <description>Sildenafil citrate 140 mg/day (single morning oral dose of 140 mg) for a total duration of 24 weeks. + advice to walk for a total duration of 6 months.&#xD;
Treatment will be proposed in addition to optimal treatment (Antiplatelet + Lipid Lowering Drugs + AT2 antagonists / ACE Inhibitors; unless contra-indicated) + advice to walk.</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (single morning oral dose) + advice to walk for a total duration of 24 weeks.&#xD;
Treatment will be proposed in addition to optimal treatment (Antiplatelet + Lipid Lowering Drugs + AT2 antagonists / ACE Inhibitors; unless contra-indicated) + advice to walk.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient ≥ 18 years old;&#xD;
&#xD;
          2. with peripheral artery disease (ABI ≤ 0.90 or TBI ≤ 0.70 or post-exercise ABI decrease&#xD;
             of 18.5% from rest or ABI Exercise TcPO2 with DROPmin ≤ 15 mmHg) reporting stable&#xD;
             limiting claudication despite optimal medical treatment (Antiplatelet + Lipid Lowering&#xD;
             Drugs + AT2 antagonists / ACE Inhibitors; unless contra-indication) and advice to walk&#xD;
             for at least 4 weeks;&#xD;
&#xD;
          3. with a walking capacity lower or equal to 500 meters on treadmill;&#xD;
&#xD;
          4. affiliation to a social security agency&#xD;
&#xD;
          5. Patient who has understood the protocol and signed the consent form to participate.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Revascularization already decided and scheduled;&#xD;
&#xD;
          2. Critical limb ischemia;&#xD;
&#xD;
          3. Life threatening disease;&#xD;
&#xD;
          4. Contraindication related to Sildenafil:&#xD;
&#xD;
               -  Patients treated with nitrates or drugs interfering with the action of sildenafil&#xD;
&#xD;
               -  Ongoing treatment by Ritonavir or alpha-blockers&#xD;
&#xD;
               -  Hypersensitivity to sildenafil or any of the excipients (lactose monohydrate)&#xD;
&#xD;
               -  Recent history of myocardial infarction or stroke &lt; 3 months&#xD;
&#xD;
               -  Severe cardiovascular disorders such as unstable angina, severe cardiac failure&#xD;
                  and cardiomyopathy&#xD;
&#xD;
               -  Hypotension (Blood pressure &lt; 90/50 mmHg)&#xD;
&#xD;
               -  Severe renal or hepatic failure&#xD;
&#xD;
               -  Amblyopia&#xD;
&#xD;
               -  Loss of vision in one eye because of Non-arterial ischemic Ophtalmic Neuropathy&#xD;
                  (NAION)&#xD;
&#xD;
               -  Known hereditary degenerative retinal disorders such as retinitis pigmentosa&#xD;
&#xD;
               -  Leukemia, Drepanocytosis, Multiple Myeloma&#xD;
&#xD;
          5. Pregnancy or breastfeeding;&#xD;
&#xD;
          6. Subjects under reinforced protection, deprived of liberty by judicial or&#xD;
             administrative decision, hospitalized without consent or admitted to a health or&#xD;
             social care establishment for purposes other than research;&#xD;
&#xD;
          7. Being in an exclusion period for another clinical study or in an ongoing&#xD;
             interventional clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Loukman Omarjee, MD</last_name>
    <phone>02.99.28.52.32</phone>
    <email>loukman.omarjee@chu-rennes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rennes University Hospital</name>
      <address>
        <city>Rennes</city>
        <state>Bretagne</state>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Loukman Omarjee, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Loukman Omarjee, MD</last_name>
      <phone>02.99.28.52.32</phone>
      <email>loukman.omarjee@chu-rennes.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Loukman OMARJEE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillaume MAHE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amiens University Hospital</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marie-Antoinette SEVESTRE, MD</last_name>
      <phone>03.22.45.59.30</phone>
      <email>sevestre.marie-antoinette@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>03.22.45.59.30 03.22.45.59.30, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bordeaux University Hospital</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Joel CONSTANS, MD</last_name>
      <phone>05.56.79.58.16</phone>
      <email>joel.constans@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Joel CONSTANS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Caen University Hospital</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Damien LANEELLE, MD</last_name>
      <phone>02 31 06 53 27</phone>
      <email>laneelle-d@chu-caen.fr</email>
    </contact>
    <investigator>
      <last_name>Damien LANEELLE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cholet Hospital</name>
      <address>
        <city>Cholet</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Cédric FONTAINE, MD</last_name>
      <phone>02 41 49 64 30</phone>
      <email>cedric.fontaine@ch-cholet.fr</email>
    </contact>
    <investigator>
      <last_name>Cédric FONTAINE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grenoble University Hospital</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Gilles PERNOD, MD</last_name>
      <phone>04 76 76 57 17</phone>
      <email>GPernod@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Gilles PERNOD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mulhouse Hospital</name>
      <address>
        <city>Mulhouse</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Amer HAMADE, MD</last_name>
      <phone>03 89 64 70 80</phone>
      <email>hamadea@ghrmsa.fr</email>
    </contact>
    <investigator>
      <last_name>Amer HAMADE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nîmes University Hospital</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Antonia PEREZ MARTIN, MD</last_name>
      <phone>04 66 68 33 13</phone>
      <email>antonia.perez.martin@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Antonia PEREZ MARTIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP - Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Tristan MIRAULT, MD</last_name>
      <phone>01 56 09 58 32</phone>
      <email>tristan.mirault@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Tristan MIRAULT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Paris Saint-Joseph and Hospital Marie Lannelongue</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Yann GOUËFFIC, MD</last_name>
      <phone>01 44 12 75 91</phone>
      <email>ygoueffic@hpsj.fr</email>
    </contact>
    <investigator>
      <last_name>Yann GOUËFFIC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint-Etienne University Hospital</name>
      <address>
        <city>Saint-Etienne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toulouse University Hospital</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Arthur THERY, MD</last_name>
      <phone>05.61.32.39.10</phone>
      <email>thery.a@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Arthur THERY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 24, 2018</study_first_submitted>
  <study_first_submitted_qc>September 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2018</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Intermittent Claudication</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

